According to preliminary statistics from VCBeat, 13 financing events were identified in China's healthcare sector between November 17 and 21, 2025 (excluding IPOs and private placements), with the largest disclosed transaction being a Series A+ round of RMB 500 million by Reprogenix Bioscience.

